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Abstract 
Obesity and metabolic side effects such as diabetes mellitus are major concerns in public health. 
Mentally ill people are a high risk subgroup for obesity and metabolic syndrome because of 
behavior, non treatment, and medication side effects. In this research, I conducted a retrospective 
chart review to compare the weight and body  mass index of consumers who were prescribed 
antipsychotic Type 1 or Type 2 medications. The sample was drawn from consumers attending 
the Consumer Advocacy Model (CAM) program which is an outpatient substance abuse and 
mental health treatment program in the Wright State University Boonshoft School of Medicine 
Department of Community Health.  
The primary aim of the study was to evaluate this local clinical population and make 
recommendations in the context of upcoming universal health coverage plan for prescribing 
antipsychotic medications. This is based on lowering the cost and increasing effectivity of 
medication use in  treatment for this population.  
Method: Medical charts of 195 patients seen at the Consumer Advocacy Model (CAM) Urbana, 
Ohio location were reviewed, and this data was analyzed. A review of other patients ‘subjective 
experiences were also gathered from the Consumer Health Resource Group, (Consumer Health 
Reports, 2011). 
Results: During a period of four months, 42 patients were prescribed risperidone; 59 were 
prescribed olanzapine; 53 were prescribed Seroquel; and 46 were prescribed three other 
antipsychotics.  The predominant adverse effects produced by most of the antipsychotic Type 2 
drugs consisted of weight gain and sedation.  
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Conclusion: This data analysis raises awareness that obesity is a major health risk factor with the 
use of Type 2 antipsychotic drugs. Suggestions for identifying expected weight gain in the 
consumers as well as addressing negative health consequences of obesity are discussed.  
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Introduction and Literature Review
During the 1950’s the first antipsychotic medication was discovered. Antipsychotics are 
broadly divided into two groups, the typical or Type 1 or first-generation antipsychotics and 
the atypical or Type 2 or second-generation antipsychotics. The Type 1 antipsychotics are 
classified according to their chemical structure while the Type 2 antipsychotics are classified 
according to their pharmacological properties.  
Antipsychotic drugs are prescribed with increasing frequency to people with an 
expanding variety of diagnoses such as schizophrenia, schizoaffective disorders, bipolar 
disorders, and schizophreniform disorders (Brannon, 2011). Early investigators noted the striking 
ability of the first such drugs to produce a patient state characterized by mental slowing, apathy, 
and emotional indifference (Moncrieff, Cohen, & Mason, 2009). Subsequent studies with 
volunteers and first person accounts by patients also emphasize the emotional detachment, 
reduced initiative, dysphoria, and akathisia produced by these drugs. Over the years, various 
labels have been used to describe these effects, including neuroleptic induced dysphoria, akinetic 
depression, neuroleptic induced deficit syndrome, and behavioral toxicity (Challoner, 2010).  
An antipsychotic is a tranquilizing psychiatric medication primarily used to manage 
psychosis. Many physicians are now prescribing the Type 2 antipsychotic medications for 
schizophrenia and bipolar disorders, and this has led to increased risk for diabetes mellitus and 
the development of metabolic syndrome, which can present as weight gain, hypertriglyceridemia, 
as well as increased insulin, glucose and low-density lipoprotein cholesterol levels (Zagaria, 
2011). Treatment with Type 2 antipsychotics may increase the risk of metabolic syndrome and 
diabetes (Lieberman, 2004a; Newcomer, 2007).  
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The right balance of treatment for schizophrenia in terms of risks versus benefits is very 
important and current professional guidelines for these medications recommend that Type 1 
antipsychotic medications have the same efficacy as Type 2 but do not lead to obesity (Mandell, 
Unis, & Sackett, 2011). There is also short term versus long term cost benefit for the use of Type 
1 antipsychotic medications rather than Type 2 medications which are expensive for the 
consumer to use.  
Obesity and Metabolic Syndrome are Public Health Problems
Obesity and complex metabolic syndrome,which includes insulin resistance and diabetes 
mellitus, are major public health issues. Obesity is increasing substantially and is one of the 
major contributors of disease prevalence due to its pathophysiological link to other 
cardiovascular risks such as hypertension and diabetes. According to the World Health 
Organization’s recent update, diabetes, hypertension, and obesity are among the top five 
continuing risk factors for cardiovascular deaths in the world (Motlagh, O'Donnell, & Yusuf, 
2009). It is estimated that in 2010, 6.4% of adults had diabetes mellitus affecting 285 million in 
the world and it is expected to increase to 7.7% by 2030, affecting 439 million adults (Shaw, 
Sicree, & Zimmet, 2010). Of special note is the expected 67% increase in the prevalence of 
diabetes in developing countries  by 2030 (Shaw et al., 2010). 
In a metanalysis using data from 1.46 million adults, Berrington de Gonzalez and 
colleagues (2010) further confirmed that overweight and obesity significantly increases the risk 
of mortality. The analysis pooled together data from 19 prospective studies that followed 
participants an average of 10 years and found that as BMI increased above the normal range 
(BMI = 18.5 - 24.9), the risk of premature death increased. Those in the obese category (BMI = 
30 - 34.9) had a 44 percent higher risk than normal, while those with a BMI of 40 - 49.9 had 
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more than double the risk of premature death. Perhaps the most notable finding from this 
research is the sustained increase in mortality seen in the overweight category (BMI = 25 - 29.9), 
something not found in some previous large studies (Dart & Colditz, 2010).  
Use of Antipsychotics and Obesity Statistics 
In 2009, IMS Health estimates that U.S. consumers filled 52 million prescriptions for 
atypical antipsychotic medications, which account for the vast bulk of antipsychotic medications 
prescribed today (Healy, 2011). A consensus panel for monitoring the metabolic effects of Type 
2 antipsychotic medicationsnoted at 10 weeks of treatment with an atypical antipsychotic 
medication for schizophrenia or psychotic disorder that there was an estimated average weight 
gain with drug treatment compared with a placebo. The weight gain varied from 0.5 to 5.0 kg 
with the use of Clozapine, Seroquel, Risperidone, Olanzepine, Abilify@, and Geodon (Barrett, 
2004). 
Effects of Obesity on the General Population 
Nearly one-third (32.9%) of U.S. adults are obese (nearly 72 million adults) (Ogden, 
Lamb, Carroll, & Flegal, 2010). Obesity is a social stigma and has a great public health impact 
(Puhl & Heuer, 2010). Additionally, obese and overweight people are very likely to experience 
discrimination in a variety of forms (Levi, Vintner, Richardson, St. Laurent, & Segal 2009). 
Obesity has very serious effects on physical health. Some examples are given in the Table 1.  
Healthy People 2020 Goals 
Despite national efforts, obesity is still a major public health problem. As a public health 
problem, obesity is addressed in Healthy People 2020 goals. The goals for 2020 include reducing 
obesity by 10 percent. (Healthy People, 2011). 
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Obesity rates have recently reached 30 percent in some states, according to the Centers 
for Disease Control and Prevention (2010). However, chronic diseases that are highly 
preventable, such as heart disease and diabetes, that are directly linked to obesity are still 
responsible for seven out of every 10 deaths among Americans each year and account for 75 
percent of the nation’s health spending (Healthy People, 2011). 
Cost and Economic Burden of Obesity 
The annual medical costs of obesity in the United States were estimated to amount to 75 
billion dollars in 2003 (Finkelstein, Ruhm, & Kosal, 2005) and responsible for between 4.3% 
and 7% of total health care expenditure. It is worth noting that the annual revenues for all 
antipsychotic drugs are $14.6 billion (Wilson, 2009).  
Dart and Colditz (2010) examined the relationship between the obesity trend and 
increases in US health expenditures. They found that the combination of rising obesity 
prevalence and increased spending among the obese accounts for 27% of the growth in US 
health care expenditure between 1987 and 2001. The latter effect signifies the changes in 
standard care for diabetes, hypertension, hyperlipidemia, and heart disease (Dart & Colditz, 
2010). 
Thompson, Edelsberg, Kinsey, and Oster (2010) estimated absenteeism in the US due to 
obesity cost employers $2.4 billion in 1998. The estimated workday loss among the very obese 
(BMI ≥ 40 or BMI ≥ 35 and with comorbidities) derived from the 2002 National Health 
Interview Survey amounts to approximately four days per year for men and 5.5 days per year for 
women (Finkelstein et al., 2005).  
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 Mental Illness, Physical Activity and Obesity
With obesity  at epidemic levels, it is the second leading cause of preventable death in the 
United States because of its association with cardiovascular disease (Evans, Renaud, Finkelstein, 
Kamerow, & Brown, 2006). The prevalence of excess weight is even higher among adults with 
severe mental illness, and many of these adults have other chronic conditions such as diabetes, 
heart disease, hypertension, or pulmonary disease (Jones et al., 2004). Obesity is significantly 
associated with the use of antipsychotic medications for any mood disorder, major depressive 
disorder, any anxiety disorder, and most strongly with some individual anxiety disorders such as 
post-traumatic stress disorder (PTSD) (Scott, McGee, Wells, & Oakley Browne, 2008). 
Weight gain is seen with the use of Type 2 antipsychotic medications (Ascher-Svanum, 
2005). During the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) trial , 
patients taking olanzapine gained an average of 0.9 kg per month. Patients taking quetiapine and 
risperidone showed minimal weight gain (0.5 kg and 0.36 kg increase from baseline, 
respectively), and those taking ziprasidone experienced weight loss (-0.72 kg) (Liberman, 
2004a). To minimize weight gain and metabolic effects, it’s suggested to use Abilify, Latuda, 
Saphris, or Geodon but not Zyprexa, clozapine, or Seroquel (Shaw et al., 2010). 
Obesity can be an obstacle to adherence to medication, as evidenced by a mail survey of 
persons with schizophrenia where BMI status and subjective distress from weight gain were 
predictors of noncompliance (Citromea & Vreeland, 2009). Sometimes patients complain about 
the weight gain and these side-effects can be removed by simply reducing the patient's 
antipsychotic drug dosage or by switching the medication; unfortunately, such reduction in drug 
dosage or switching to another medication often causes patients to relapse back into psychosis 
(Grohl, 2010). The quality of life associated with schizophrenia ranks among the worst of any 
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chronic medical illness, and treatment with atypical antipsychotics may improve the quality of 
life for many of these patients (Liberman, 2004b). 
In the third quarter of calendar year 2010 (July-September 2010), the Centers for 
Medicare and Medicaid (CMS) reports that nationwide 39.4% of nursing home residents who 
had cognitive impairments and behavior problems but no diagnosis of psychosis or related 
conditions received antipsychotic drugs (CMS, 2010). It has been reported that approximately 
one-quarter of nursing home residents, nearly 350,000 people , take antipsychotic drugs (Wilson, 
2009; Ray et al., 1993). With the use of antipsychotic medications additional side-effects of 
obesity are being added to the consumers’ guidance information issued by CMS ( 2011) which 
encourages facilities to use non-pharmacological alternatives and identifies situations where 
antipsychotic medications are not indicated.  
In a study by NIMH (2008), effects of Type 2 antipsychotic medications were studied in 
children and adholescents. This study covered 272 patients visiting clinics from 2001 to 2007. 
Fifteen patients who stopped taking their medicine were used as a control group. The weight for 
the control group stayed level. The 257 patients who stayed on their drugs took detailed tests, 
including a fasting blood test to check for metabolic markers for obesity which can presage adult 
obesity, hypertension, and Type II Diabetes Mellitus. The metabolic markers included glucose, 
insulin, triglycerides,and cholesterol (Wilson, 2009). Their mean weight at the start of the study 
period was 118 pounds. But after about 11 weeks, those who took Zyprexa had gained 18.7 
pounds; Seroquel, 13.4 pounds; Risperdal, 11.7 pounds; and Abilify, 9.7 pounds. Their waists 
typically expanded three inches with Zyprexa, and two inches with the other medications. All but 
Abilify showed rapid and significant increases in one or more metabolic markers. A similar 
study saw weight gain in adults with the use of antipsychotic medications predominantly 
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Zyprexa and risperidone for a 10 week period (Nauret, 2009). It has also been demonstrated that 
even untreated patients suffering from schizophrenia are at an increased risk of developing 
medical conditions associated with metabolic syndrome (Gautam & Meena, 2011; Lieberman, 
2004b). 
Regular physical activity is one of the few health behaviors with demonstrated benefits 
for weight loss as well as related conditions such as hypertension, cardiovascular disease, and 
diabetes (DHHS, 2008a; DHHS, 2008b). Physical activity levels in adults with severe mental 
illness are not well studied, although available evidence suggests this group is less active than the 
general population (Daumit, 2010). Psychological symptoms and low cognitive functioning may 
also pose a barrier to regular physical activity as evidenced by a previous study which found that 
adults with intellectual disabilities had higher levels of physical inactivity compared to the 
general population estimates of physical activity (Robertson et al., 2000). Additionally, persons
with mental illness report that negative affective states (e.g., sadness, depression) as well as 
mental illness symptoms are barriers to their participation in physical activity (McDevitt, Snyder,
Miller, & Wilbur, 2006; Ussher, Stanbury, Cheeseman, & Faulkner, 2007). 
Risk of Developing Diabetes with Antipsychotic Medication
Use of Type 2 antipsychotic medications are problematic compared to the use of Type 1 
antipsychotic medications which are associated with less incidence of metabolic syndrome 
(Lieberman, 2004a). For individuals with co-occurring heart disease or diabetes, this issue is of 
particular importance, especially when the patients present for treatment (Sicras-Mainar,
Navarro-Artieda, Rejas-Gutierrez, & Blanca-Tamayo, 2008).
In a multicenter randomized prospective study, Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE), 1493 patients with schizophrenia were randomized to 
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receive typical antipsychotic, perphanazine, or the atypical antipsychotics, olanzapine, quetiapine 
or risperidone for 18 months or until discontinuation due to tolerability failure by the patients. In 
this study, olanzapine was associated with the greatest degree of weight gain, estimated at 0.9 
kg/month and an increased fasting blood glucose levels greater than 140 mg/ld. on at least two 
occasions. Interestingly, a few antipsychotic agents such as molindone (Type 1 antipsychotic), 
geodon and aripiprazole appear to have a slight weight reducing effect in previous studies. 
(Lieberman, 2004b). 
Methodology 
Databases resident at the CAM program allowed a retrospective analysis by comparing 
the baseline and three month follow-up of weight and body mass index of persons with mental 
illness who have recently used or who have not used psychotropic medication. This study 
originally intended to compare three groups of persons with diagnosed mental illness: 1) Persons 
using Type 1 antipsychotics; 2) persons using Type 2 antipsychotics; and 3) persons taking no 
antipsychotic medication. However, all individuals in the study who were taking Type 1 
antipsychotics were also prescribed Type 2 antipsychotics leading to the decision to include them 
as one group. The final three participant groups for this research were: 1) persons taking Tpye 2 
antipsychotics; 2) people taking both Type 1 and Type 2 antipsychotics; and 3) people taking no 
antipsychotices. Self-reported psychotropic use for the past 30 days was used for the 
categorization variable.
Data collection was from a retrospective chart review. The record review  focused on past 
CAM consumers ages 18 and over who attended CAM during 2010-2011 for a period of three 
months. The data of 195 patients that were seen at CAM in Urbana, Ohio was obtained. The 
reviewed cases were randomly selected from all the patients who had height and weight 
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measurements noted at intake and three months after the use of antipsychotic medications. Seven 
patients were taken out of the study because they were less than 18 years old and one who had a 
diagnosis of mental retardation.  
SPSS 17.0 was used for analysis. Since there was no single patient on Type 1 
antipsychotic medication alone, there was an assigned Group in SPSS for consumers taking Type 
1 and Type 2 antipsychotic medications. An independent t test analysis was used and compared 
the following: 1) Group with the cohort taking Type 2 antipsychotic medications only; 2) Group 
versus consumers who were taking medications other than antipsychotic medications; and 3) 
Type 2 versus consumers who were taking other medications. The General Linear Model (GLM) 
which approximates ANCOVA and compares means of three groups was also used. The 
dependant variables were BMI and change in BMI. Thefixed factor was group, and the 
covariates were age, race, and sex.
Use of inductive data 
This study also included an examination of data from the Consumer Health Resource 
Group, LLC (Consumer Health Reports, 2011) that compiles uncensored user comments on the 
effects of taking different medications from people with a range of mental health diagnoses. Both 
a qualitative and quantitative analysis was conducted on data from patients taking two of the 
most widely prescribed Type 2 antipsychotic medications, olanzapine and risperidone, and 
patients taking the Type 1 antipsychotic medications haloperidol and chlorpromazine. In 
addition,information about how the reported effects of the antipsychotics interacted with the 
symptoms for which people were treated was reviewed. Respondents can record comments about 
a range of medicines which they are taking or have taken, including many drugs used in 
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psychiatry. Basic demographic information in separate fields, including t age, gender, diagnosis 
and the length of time they have been taking the drug was recorded and reviewed.  
Variables for CAM study 
The following variables were used to analyze the data from CAM records: 1) ID number; 
2) Traumatic brain injury; 3) Medication listed at intake and prescribed treatment; 4) Group by 
Type 1 and Type 2; 5) Demographics: age, gender, race/ethnicity; education level; 6) DSM IV 
diagnosis; and 7) History of special education, borderline intellectual functioning, ADHD 
learning disorder; and comorbid medical or mental health conditions. 
To compare prevalence of weight gain, hyperglycemia, hypercholesterolemia, 
hypertriglyceridemia, among consumers taking Type 1 or Type 2 antipsychotic medications. 
SPSS was used to run basic descriptive statistics independent t-test and ANCOVA (Analysis of 
Covariates). It is a General Linear Model analysis which compares the means between the three 
groups, making change in weight and BMI as dependant variables, group as fixed factor 
(medication Type 1 and Type 2, Type 2 or no medication) and making age, sex and race as 
covariates. 
Results 
Descriptive statistics and independent t test 
Descriptive statistics for age are presented in Table 5. Males and females across all three 
groups were of similar ages (all independent t test, p > 0.05). The only group that was different 
in age for males was males not taking antipsychotics were significantly different from males 
taking antipsychotics (p=0.046). For females, those not taking antipsychotic were significantly 
younger then those taking Type 1 and 2 (p=0.016) and those taking Type 2 (p=0.002). 
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Descriptive statistics for weight and BMI are presented in Table 6. There was no 
significant difference in initial weight of males and females across the three groups. Initial BMI 
was significantly different for men on Type 2 then men on no antipsychotic medication 
(p=0.002). There was no significant difference in change in weight in males or females taking 
Type 2 antipsychotics and those taking Type 1 and 2 antipsychotic medications (all p > 0.05). 
BMI and change in BMI in 3 months for individuals on antipsychotic medications 
In order to determine if Type 2 was associated with greater initial and changes in BMI we 
compared the means of Group taking Type 1 and Type 2 antipsychotic medications versus Type 
2 antipsychotic medications alone. Table 7 shows this. Nonsignificant effects of Group were 
seen on the BMI initially and after 3 months. 
General Linear Model (GLM) analysis
GLM compares the means between the three groups. It can be used for ANOVA or 
ANCOVA (Analysis of Covariates). Change of Weight in 3 months by the use of antipsychotic 
Type 2 medications using a general linear model analysis making change in weight and BMI as 
dependant variables and making Group as fixed factor and making age, sex and race as 
covariates. Table 7 shows this GLM for the change in weight.  
It can be seen from the table 7 a multivariate analysis of change in weight is carried out 
using GLM model with independent variables age, sex race, group. It shows significant 
(p=<0.000) effect across Group which is the fixed factor to that of change in weight in 3 months 
of using the antipsychotic medication. The R2 is 67%, showing that the variables in the model 
explains the 67% of the variance in change in weight. The significance of sex can be explained 
by the fact that there is almost the same kind of weight gain in women on Type 1 and Type 2 
antipsychotic medications and Type 2 alone, but in case of men there is a significant weight 
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increase with the use of Type 2 antipsychotic medications alone which can be explored further. 
More simply, women gained more weight then men.  
Figure 1 and Figure 2 illustrates the results of the change in weight. There is a significant 
weight change in the groups being prescribed Type 1 and Type 2 antispsychotic medications and 
Type 2 antipsychotic medications alone compared to the patients’ prescribed no antipsychotic 
medication. 
A similar significant effect of medication group on the dependent variable change in BMI 
can be seen in table 8 using independent variables sex, age, race and group. Only Group was 
significant (p=<0.0001). 
Discussion
Obesity policy versus guidelines 
Some of the public health policies have been laid down to prevent the development of 
obesity. These policies can be helpful for patients who are taking Type 2 antipsychotic 
medications and experience weight gain. Some examples are given below:
 Mass media health promotion campaigns that emphasize healthful eating and 
physical activity patterns. 
 Require and fund daily physical education and sports programs in primary and 
secondary schools. 
 Develop culturally relevant obesity prevention campaigns for high-risk and low-
income Americans.   
 Require chain restaurants to provide information about calorie content on menus 
or menu boards and nutrition labeling on wrappers.  
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 Protect school food programs by eliminating the sale of soft drinks, candy bars, 
and foods high in calories, fat, or sugar in school buildings.   
 Require health care providers to learn about behavioral risks for obesity and how 
to counsel patients about health-promoting behavior change.   
 Use the National Nutrition Summit to develop a national campaign to prevent 
obesity. 
	 Develop a coordinated federal implementation plan for the Healthy People 2020 
nutrition and physical activity objectives. as Type 2 antipsychotic medications 
have a tendency to cause weight gain. 
All of these public health policies can help in patients on Type 2 antipsychotic 
medications if they follow them from day 1 of the there antipsychotic medication prescription 
(Papolos & Papolos, 2000). 
Physical activity guidelines 
The Physical Activity Guidelines for Americans ((DHHS, 2008a) indicates that regular 
physical activity reduces the risk of many adverse health outcomes. Some physical activity is 
better than none (DHHS, 2008a; CDC, 2011). Most health benefits occur with at least 150 
minutes (2 hours and 30 minutes) a week of moderate intensity physical activity, such as brisk 
walking. The benefits of physical activity far outweigh the possibility of adverse outcomes 
(DHHS, 2008b). 
Risks versus benefits of antipsychotic treatment 
The quality of life associated with schizophrenia ranks among the worst of any chronic 
medical illness, and treatment with Type 2 antipsychotics may improve the quality of life for 
many patients. The greatest advantage of atypical antipsychotics is their ability to improve 
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cognition, since impaired cognition is now considered to be a fundamental feature of 
schizophrenia. Type 2 antipsychotics have been shown to significantly improve many aspects of 
cognitive function, including executive function, verbal fluency, attention, memory and learning 
impairment (Liberman, 2004b). Physicians must weigh the risks and benefits for each patient
before beginning an antipsychotic treatment. The patient and the primary care provider must 
work together to outline potential risk factors and to carefully monitor risks during treatment.  
In this small retrospective cross-sectional study, our findings are consistent with previous 
evidence in the literature, which suggests patients treated with Type 2 antipsychotic medication 
may be at increased risk of hyperlipidemia and hyperglycemia then people who were placed on 
second generation antipsychotic medication. So the question is whether to put the patient into the 
risk of development of metabolic side effects or to use antipsychotic medications Type 1? The 
decision depends on each case, the family history and risks of developing metabolic side effects 
for the patients.
The guidelines recommend routine monitoring of drug levels every 6 months. Routine 
monitoring of drug levels is required to gauge adequate dosing and to detect potential toxic 
levels that can lead to side effects and comorbidity. Referring the patient population on 
antipsychotic medications with abnormal glucose or lipid levels for a medical checkup. 
Encourage weight loss. Be alert of the possibility of diabetic ketoacidosis. Support moderate 
exercise and discourage smoking. Consider discontinuing the antipsychotic medications because 
it will resolve hyperglycemia and diabetes in some cases. 
Limitations of the Current Study 
The study is on the basis of 195 patients who were seen at CAM in Urbana. This is a 
small pool of patients, but it illustrates effects seen in larger clinical studies such as the CATIE 
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study. Only a three month period of medication use was studied, and the weight gain could even 
out with longer medication use. 
Most number of patient population seen in the CAM clinic were caucasian and only 10% 
were black. So an even number of patients in the study may tell us the difference in the weight 
gain in terms of race.
The patient’s weight gain could be due to several other reasons beside the antipsychotic 
medication itself. It could be the time period when the patients were enrolled in the study. Many 
patients were enrolled during holidays from December to April, 2010-2011. During this holiday 
mood people in general have a tendency to eat more then usual so the weight gain that was seen 
in patients on antipsychotic Type 2 medication could be related to the holiday mood and not due 
to the antipsychotic Type 2 medication itself, but more studies needs to be done in order to find 
out if antipsychotic medications have an effect on patients’ behavior to eat more or craving for 
food. More studies needs to be done to find out the comorbidities or behavioral patterns of 
mildly intellectually disabled patients.  
Recommendations
Prescribe Type 1 when possible 
It shows Type 2 antipsychotic medications especially risperidone, seroquel, olanzepine, 
abilify increases the patients weight over the time and also in some cases have produced diabetes 
mellitus. It is a public health issue as being studied in multiple study trials because sheer number 
of people on it. People sometimes take it off label or on label especially in the elderly population. 
This concern should be addressed by using antipsychotic medications like Geodon, Invega or 
other new Type 2 antipsychotic medications which cause less weight gain. 
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Address weight gain by increasing the physical activity 
Restlessness and confusion can be one of the side-effects with the use of antipsychotic
medications especially if it is combined with alcohol and anxiolytic medications. With this 
confused state of mind and fall risk, patient’s have a hard time to exercise or do any kind of 
physical activity. This might be the reason patients are at risk of gaining weight and developing 
the risk of diabetes mellitus. Certain programs should be developed for patients who are taking 
antipsychotic medications which could urge them to participate in some kind of exercise 
programs. Further studies should be done to develop a physical activity questionnaire for the 
patient population on antipsychotic medications. 
Physicians should include a more public health perspective in their practice 
Table 3 shows Type 1 medications are cheaper and in some cases is also offered as a $4 
generic prescription compared to the antipsychotic medications. With the universal health 
insurance plan this should be an appropriate cost effective plan given the side-effects of the 
antipsychotic medications. 
Annual revenues for all antipsychotic drugs are $14.6 billion (Wilson, 2009). Atypical 
antipsychotic drugs cost more than $13 billion in 2007, "nearly 5 percent of all U.S. drug 
expenditures" and are a major expenditure for Medicare Part D (Alexander, Gallagher, Mascola, 
Moloney, & Stafford, 2011). From a public health perspective cost effective treatment with the 
use of Type 1 antipsychotic medications rather than Type 2 antipsychotic medications should be 
encouraged however this can be decided on case by case basis. 
Public health should add to the clinical perspective especially with universal health 
insurance coming up. Type 2 antipsychotic drug use can be associated with weight gain and 
development of insulin resistance and dyslipidemia. Treatment of this condition requires 
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coordination with the treating psychiatrist, close monitoring of their metabolic complications and 
the use of lifestyle intervention as well as adjuvant medical therapy as necessary. Each patient 
should be managed on a case by case basis with consideration of the degree of underlying 
psychiatric illness as well as previous responses to her antipsychotic agents and their individual 
risk factors for metabolic syndrome.  
Listen to patients’ feedback and concerns
Studies have found that clinicians ignore or minimize patient’s complaints about the 
negative subjective effects of antipsychotics (Moncrieff et al., 2009). To improve patient’s 
experience, doses of antipsychotics should be kept as low. Approaches that attempt to avoid or 
minimize the use of antipsychotics could also be explored further. Overall, prescribers need to 
take subjective effects of medications seriously and doctors and their patients should take into 
account the public health perspective regarding treatment such as the cost analysis and 
medication side effects. The patients need to be informed for every step of change taken during 
the treatment and the nature of these effects in order to make informed judgments about their 
use. 
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Appendix A 
Glossary
Akathisia: An inability to remain motionless or sit still.
Akinetic: Absence or lack of movement. 
BMI: Body Mass Index (BMI) is a number calculated from a person's weight and height..      
Abnormal metabolic levels and BMI are defined by  the National Cholesterol Education 
Program (NCEP) and World Health Organization (WHO) criteria as follows: 1) an abnormal 
BMI between 25 and 29.9 for overweight and equal to or greater than 30 for obesity; 2) an 
abnormal blood glucose level equal to or greater than 110 mg/dl (equal to or greater than 
126 mg/dl for diabetes); 3) an abnormal blood cholesterol level equal to or greater than 200 
mg/dl; 4) an abnormal blood triglyceride level equal to or greater than 150 mg/dl (Tarricone, 
2006). 
Dysphoria: An unpleasant or uncomfortable mood, such as sadness. 
Dystonia: Sustained muscle contractions that cause twisting and repetitive movements 
or abnormal postures. 
EPS: Extrapyramidal symptoms (EPS) are various movement disorders such as acute
dystonic reactions, or akathisia suffered as a result of taking dopamine antagonists, usually 
antipsychotic (neuroleptic) drugs. 
Hypertriglyceridemia: An increased blood triglyceride level; a possible risk factor for 
cardiovascular disease.  
Metabolic Syndrome: Metabolic syndrome is a condition characterized by impaired 
glucose regulation, diabetes type I, insulin resistance, raised arterial pressure > 160/90 mm Hg, 
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raised plasma triglyceride levels, raised LDL, cholesterol level, and/or BMI > 30 kg/m2, and 
microalbuminuria (Alberti, 2009). 
Tardive Dyskinesia: A condition that is characterized by repetitive, involuntary, 
purposeless movements, such as grimacing, tongue protrusion, lip smacking, puckering and 
pursing of the lips, and rapid eye blinking. 
Type I (Typical) Antipsychotic Medications: Haldol, chlorpromazine, Loxapine and 
thorazine, are the most commonly known typical antipsychotic medications. 
Type II (Atypical) Antipsychotic Medications: The newer antipsychotic medications 
such as Zyprexa, olanzepine, seroquel, risperidone, Latuda, fanapt and abilify are commonly 
prescribed Type 2 antipsychotic medications. 
Unless otherwise cited all definitions cited verbatim,  Venes, 2010. 
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Appendix B 
Table 1: Effects of obesity on physical health  
Cardiovascular 
• Hypertension 
• Congestive heart failure 
• Cor pulmonale (Pulmonary Hypertension) 
• Coronary artery disease
Endocrine 
• The metabolic syndrome
• Type 2 diabetes 
• Dyslipidemia (Cholesterol problems) 
Gastrointestinal 
• Gastroesophageal reflux disease (GERD)
• Cholelithiasis (Gall Stones)
Genitourinary 
• Pregnancy complications 
Musculoskeletal 
• Osteoarthritis (knees, hips) 
• Low back pain 
Neurologic 
• Stroke 
Psychological 
• Depression/low self esteem 
Respiratory 
• Obstructive sleep apnea 
• Asthma
(Kushner and Roth , 2003) 
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Table 2: Type 1 Antipsychotic medications prescribed for and side effects 
Type 1 Brand Names Prescribed For Known Side 
Effects
Chlorpromazine Thorazine Schizophrenia, 
vomiting
Akathisia,
Fluphenazine Prolixin Schizophrenia Parkinsonism 
Haloperidol Haldol Schizophrenia EPS 
Loxapine Loxitane Schizophrenia Weight Gain 
Molindone Moban Schizophrenia NMS 
Perphenazine Trilafon Schizophrenia TD 
Pimozide Orap Schizophrenia EPS 
Thiothixine Navane Schizophrenia EPS 
Trifluopromazine Vesprin Schizophrenia EPS 
NMS=Neuromalignant syndrome, EPS= Extrapyramidal side effects, TD=Tardive Dyskinesia 
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Table 3: Type 2 Antipsychotic medications prescribed for and side effects 
Type 2 Brand Name Prescribed For Known Side 
Effects
Aripiprazole Abilify Schizophrenia, 
Bipolar 
Wt. gain, 
Akasthesia 
Asenapine Saphris Schizophrenia, 
Bipolar 
Akasthesia 
Clozapine Clozaril Schizophrenia Sedation, 
Agranulocytosis 
Lurasidone Latuda Schizophrenia Akasthesia 
Olanzepine Zyprexa Schizophrenia, 
Bipolar 
Wt. gain, 
Akasthesia 
Paliperidone Invega Schizophrenia Wt. gain, 
Akasthesia 
Risperidone Risperdal Schizophrenia, 
Bipolar 
Wt. gain,  
breast enl, 
Akasthesia 
Quetiapine Seroquel Schizophrenia, 
Bipolar, Insomnia 
Wt. gain, 
Akasthesia 
Ziprasidone Geodon Schizophrenia Wt. gain, 
Akasthesia 
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Table: 4 Cost Analysis for Antipsychotic medications 
Type Medication Dose 30 
day 
supply 
Cost 
without 
Insurance 
Cost 
with
Medicaid
Cost 
with
Anthem 
$4 
plan 
II Abilify 2,5,10,15 30 $450 $2.00 $10 No 
II Abilify 20,30 30 $600 $2.00 $20 No 
II Seroquel 5,100 30 $500 $2.00 $10 No 
II Seroquel 200, 400, 
600 
30 $930 $2.00 $20 No 
II Olanzepine 5,10,20 30 $275 $2.00 $15 No 
II Risperidone 0.5,1,2,3, 
4 
30 $250 $0.00 $10 No 
I Haloperidol 5, 10 30 $25-$50 $0.00 $10 Yes 
I Prochlorperazine 5,10 30 $25 $0.00 $10 Yes 
I Loxapine 5, 10, 50 30 $25 $0.00 $10 Yes 
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Table 5: Demographics 
Age
35 

Type 1 & 2 Antipsychotics Type 2 Antipsychotics No Antipsychotics
 Males 
N=30 
    Females     
N=39 
Total 
N=69 
Males 
N=85 
Females 
N=41 
Total 
N=126 
Males 
N=27 
Females 
N=39 
Total 
N=66 
x sd X 
sd x sd x sd 
x sd 
x sd x sd x sd  x sd 
35.5 10.4 34.5 9.3 35.5 10.0 37.0 10.6 36.4 10.6 36.8 10.6 32.4 9.41 29.3 9.3 30.5 9.4 
    X= mean and sd= standard deviation.       
Overall Total 
x sd 
34. 6 10.6 
( Where x= Mean and sd= Standard Deviation). 
 
   
    
   
    
   
    
    
    
   
    
   
 
Table 6: Weight and BMI Data (mean + sd) 
Antipsychotic 
Medication 
None Type 1 & 2 Type 2 
N=66 
(M = 27, F = 39) 
N=69 
(M =30 , F =39 ) 
N=126 
(M =85 , F =41 ) 
Initial Weight (kg) 
M 149.3 + 14.1 153.4 + 13.3 155.4 + 15.6 
F 141.4 + 18.3 156.6 + 17.2 153.2 + 15.6 
Overall 145.5 + 16.3 153.5 + 15.2 154.4 + 15.6 
3 month weight (kg) 
M 149.6 + 14.1 162.1 + 14.6 164.1 + 16.5 
F 141.5 + 18.3 167.4 + 18.0 164.2 + 10.1 
Overall 145.5 + 16.3 164.5 + 15.2 164.5 + 13.3 
Weight change (kg) 
M 0.30 + 0.60 6.7 + 3.1 8.7 + 4.5 
F 0.08 + 0.42 10.8 + 1.2 10.9 + 1.2 
Overall 0.05 + 0.35 8.4 + 6.2 9.2 + 10.3 
Initial BMI
M 22.5 + 1.9 24.7 + 1.7 24.0 + 2.2 
F 22.1 + 2.5 26.2 + 2.3 25.3 + 2.3 
Overall 23.8 + 2.2 25.2 + 2.0 25.0 + 2.2 
3 month BMI 
M 22.5 + 1.9 25.6 + 1.8 26.9 + 2.4 
F 22.1 + 2.5 26.4 + 2.2 27.1 + 2.2 
Overall 23.8 + 2.2 26.0 + 2.0 27.0 + 2.3 
BMI Change 
M 0.0 + 0.0 0.9 + 0.1 2.9 + 0.2 
F 0.0 + 0.0 0.2 + 0.1 2.1 + 0.1 
Overall 0.0 + 0.0 0.8 + 0.0 2.0 + 0.1 
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Table 7: Using Independent t-test 

Change in Initial BMI and change in BMI in 3 months:
 
Std. 
Std. Error 
Group N Mean Deviation Mean
BMI Type 1 & 43 25.22 2.022 .308 
initial type 2 
Type 2 83 24.99 2.408 .264 
only 
BMI Type 1 & 43 27.226 2.0545 .3133 
Type 2 
only 
3months type 2 
83 27.001 2.4977 .2742 
Independent Samples Test 
Levene's Test for 
Equality of Variances 
t-test for Equality of 
Means
 F
Sig.
 t df 
Sig. 
(2-
tailed) 
Mean 
Differenc 
e 
Std. Error 
Difference 
95%
Confidence 
Interval 
Lowe 
r 
Upper 
BMI 
initial 
1.214 *.273 .526 124 .600 .226 .429 -.624 1.076 
.556 99.023 .579 .226 .406 -.580 1.032 
BMI 
3months 
1.701 *.195 .507 124 .613 .2244 .4429 
-
.6522 
1.100 
9 
.539 
100.70 
3 
.591 .2244 .4163 
-
.6015 
1.050 
3 
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Corrected 
Total 
5726.062 192       
    
 
 
    
    
      
      
 
Table 8: GLM analysis 
Dependent Variable:Change 
in Wt. 
Source 
Type III Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
Corrected 
Model 
3893.793a 5 778.759 79.479 0 
Intercept 58.795 1 58.795 6.001 0.015 
Sex 61.728 1 61.728 6.3 0.013 
Age 0.19 1 0.19 0.019 0.889 
Race 23.162 1 23.162 2.364 0.126 
Group 3415.002 2 1707.501 174.266 0 
Error 1832.27 187 9.798 
Total 13262 193 
a. R Squared = .680 (Adjusted R Squared = .671) 
Table 9: GLM Analysis 
Dependent Variable: Change in BMI 
Source 
Type III Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
Corrected 
Model 
Intercept 
Sex 
Age 
Race 
Group 
Error 
Total 
Corrected 
Total 
103.308a 5 20.662 14.918 .000 
11.928 1 11.928 8.612 .004 
.088 1 .088 .063 .802 
.770 1 .770 .556 .457 
1.052 1 1.052 .760 .385 
85.458 2 42.729 30.851 *.000 
258.997 187 1.385 
773.470 193 
362.305 192 
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Figure 1: Medication use and change in weight in a period of 3 months 
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Medication use and change in Weight in  a period of 3 months 
Medication Group by Sex and Time 
Figure 2: Change in Weight with the medication 
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